Efficiency of New Dose Escalation Designs in Dose-Finding Phase I Trials of Molecularly Targeted Agents

BACKGROUND: Statistical simulations have consistently demonstrated that new dose-escalation designs such as accelerated titration design (ATD) and continual reassessment method (CRM)-type designs outperform the standard “3+3” design in phase I cancer clinical trials. METHODS: We evaluated the actual...

Descripción completa

Detalles Bibliográficos
Autores principales: Le Tourneau, Christophe, Gan, Hui K., Razak, Albiruni R. A., Paoletti, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3521009/
https://www.ncbi.nlm.nih.gov/pubmed/23251419
http://dx.doi.org/10.1371/journal.pone.0051039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3521009/
https://www.ncbi.nlm.nih.gov/pubmed/23251419
http://dx.doi.org/10.1371/journal.pone.0051039

Ejemplares similares